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Genomic control of metastasis
Saroor A. Patel1, Paulo Rodrigues1, Ludovic Wesolowski1 and Sakari Vanharanta 1
Metastasis remains the leading cause of cancer-associated mortality, and a detailed understanding of the metastatic process could
suggest new therapeutic avenues. However, how metastatic phenotypes arise at the genomic level has remained a major open
question in cancer biology. Comparative genetic studies of primary and metastatic cancers have revealed a complex picture of
metastatic evolution with diverse temporal patterns and trajectories to dissemination. Whole-genome amplification is associated
with metastatic cancer clones, but no metastasis-exclusive driver mutations have emerged. Instead, genetically activated oncogenic
pathways that drive tumour initiation and early progression acquire metastatic traits by co-opting physiological programmes from
stem cell, developmental and regenerative pathways. The functional consequences of oncogenic driver mutations therefore
change via epigenetic mechanisms to promote metastasis. Increasing evidence is starting to uncover the molecular mechanisms
that determine how specific oncogenic drivers interact with various physiological programmes, and what triggers their activation in
support of metastasis. Detailed insight into the mechanisms that control metastasis is likely to reveal novel opportunities for
intervention at different stages of metastatic progression.
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BACKGROUND
Surgery can often cure primary cancers. However, considering that
metastases account for the majority of cancer-associated patient
fatalities, there is a clear unmet clinical need, and an under-
standing of how to optimally manage metastatic disease is still
lacking for most cancer types. Despite the long history of
metastasis research1 and the increase in our knowledge of the
molecular mechanisms of metastasis gained, especially over the
past couple of decades, the lack of effective therapies can at least
partly be attributed to our poor understanding of the underlying
biology. The formation of metastases is the result of a complex
multistep cascade. In its simplest form, cells must disseminate
from the primary tumour, either individually or by collective
migration, enter the circulatory system (blood or lymphatic) as
single cells or clusters, seed in a capillary bed or extravasate at a
distant organ, survive in a foreign microenvironment and establish
a secondary colony.2–4 Alternative scenarios can involve perineural
invasion, metastasis via ascites or cerebrospinal fluid and
intermediate metastases in the lymph nodes. Finally, disseminated
cells may enter cellular dormancy, or their proliferation may be
counterbalanced by death or elimination by the immune system,
resulting in latent metastasis that may only become clinically
detectable decades after primary tumour removal.5 The molecular
mechanisms that enable cancer cells to progress through these
various biological steps have been the focus of extensive
investigation.2,6,7 For example, rearrangement of the actin
cytoskeleton, modulation of the extracellular matrix (ECM) and
the recruitment of certain immune cells facilitate efficient entry
into the circulatory system.8–10 The formation of clusters of
migratory cancer cells coated with platelets and metabolic
reprogramming enable resistance to mechanical damage, innate
immune response, anoikis and oxidative stress in the blood-
stream.11–16 Arrest in a capillary bed and subsequent extravasation
is influenced by factors that control cancer cell motility and
endothelial cell disjunction.6 And, finally, the survival and
establishment of secondary colonies depend upon a variety of
factors that converge on key stem-cell support pathways, growth
factor signalling, positional and mechanical pathways and
inflammatory signalling.5,17
Despite the identification of a range of genes, molecules and
pathways that contribute towards the successful completion of
one or more of the metastatic steps, how the phenotypic traits
that confer increased metastatic fitness are regulated remains
largely unknown. Using a select set of examples of studies carried
out over the past 15 years, in this review we will discuss the
genetic and epigenetic determinants of metastasis and provide a
perspective on the origin of metastatic phenotypes.
THE GENETIC LANDSCAPE OF METASTASIS
Given the complexity of metastasis, it is not surprising that
colonisation of a secondary organ by tumour cells is highly
inefficient.18 Accordingly, the number of cancer cells found in the
circulation of patients greatly surpasses the number of detectable
macroscopic lesions, and only half the number of patients with
detectable disseminated tumour cells in their bone marrow go on
to develop overt metastases in the long term.19,20 In mouse
models, only 0.02% of melanoma cells injected into the portal vein
went on to develop macro-metastases and even cell lines
enriched for high metastatic potential suffer extensive losses
during colonisation.21–23 The presence of distinct biological
barriers and the inefficiency of cancer cells in overcoming them
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represent bottlenecks that can, at least in principle, result in the
selection of specific mutations that promote metastasis. Indeed,
extensive cancer genome resequencing efforts have explored the
genetic origins of metastases24–26 and, although a clear genetic
signature of metastasis is yet to emerge, these studies have
provided unprecedented insight into the genetic patterns of
metastatic evolution and mode of spread.
The mode of spread and timing of metastasis
The trajectory of metastatic seeding has traditionally been viewed
as an orderly multistep process from a founder cell in the primary
tumour to distant organ colonisation. However, from detailed
genetic mapping of the relationships between various regions in
primary tumours and across metastatic sites in different cancer
types, a far more complex—even chaotic—picture has emerged.
In colorectal cancer (CRC) some lymph node metastases are
related to distant metastases, whereas others are not.27 Analyses
of lymph node and distant organ metastases in CRC showed that
these two types of metastases develop through different
evolutionary mechanisms; lymph node metastases display a high
level of interlesion heterogeneity in contrast to distant metastases,
which were genetically similar to each other, suggesting that
fewer primary tumour lineages are capable of seeding distant
metastases than lymph node metastases.28 In melanoma, prostate
and oesophageal cancers, distinct subclones spread directly from
the primary tumour, each independently seeding multiple
metastases.29–32 Similarly, in renal cancer and CRC, multiple
metastases in different tissues can derive from a single subclone
present in the primary tumour.33,34 However, in other cases of
renal cancer, primary tumour clones at different stages of
evolution seed metastases to different organs.33 In one patient
with breast cancer, single-cell copy number variant (CNV) analysis
of the primary tumour and its metastasis found that a single clonal
expansion seeded the metastasis,35 whereas single-cell CNV and
single-nucleotide variant (SNV) analyses in patients with CRC
showed metastatic seeding by a single clone in one patient and
multiple clones in another.36 These examples highlight the fact
that some primary cancers contain multiple clones that are
capable of forming metastases through different routes, whereas
only one metastatic clone seems to exist in other cancers.
Another level of complexity in the genetic origin of metastases
is apparent when looking at individual metastases. In some cases,
all the cells within a metastasis appear to be derived from a single
clone (Fig. 1a, b),37,38 but individual metastases can contain
multiple cancer clones in other cases (Fig. 1c, d).29 Multiple clones
within a single metastasis can result from metastasis-to-metastasis
seeding, a process known as cross-seeding, that can lead to highly
complex patterns of tumour spread (Fig. 1c).29,32 In addition,
clones from a metastasis can reseed to form a secondary
metastasis (Fig. 1e).32 Furthermore, circulating tumour cell clusters
have been shown to be highly metastatic and give rise to
polyclonal metastasis (Fig. 1d).11,39,40 As deeper and more robust
sequencing technologies emerge, studying genetic differences at
a single-cell level will likely reveal even further complexities in the
patterns of metastatic spread.
In addition to complex seeding patterns, the timing of clinically
detectable metastatic progression varies across different metas-
tases according to the type of primary cancer and the site of
secondary disease. In pancreatic cancer, the development of a
primary tumour typically takes around 12 years, but progression
from the birth of the clone that seeds the primary to the seeding
of the metastasis is comparatively fast, taking an average of 6.8
years.41 Data from renal cancer patients suggest that, depending
on the secondary site, metastases manifest clinically at different
timepoints, with a median of 15 years for pancreatic metastases
but only 3 years for all other sites when compared with initial
diagnosis.33 This variability could be a reflection of the timing of
metastatic seeding as clones seeding metastasis to the pancreas
had genetic lesions that were associated with less aggressive
phenotypes. However, this difference could also be due, at least in
part, to different modalities and effectiveness of clinical detection
at particular sites. Late dissemination and seeding of the
metastatic clone has been suggested by data gathered from
breast cancer metastases (Fig. 1b–e).42 Likewise, advanced
metastases from pancreatic and colon cancers are often































Fig. 1 Complex temporal patterns and trajectories of metastatic dissemination. A cell acquires a set of driver mutations to form a primary
tumour (PT). Aggressive primary tumour clones invade, circulate and seed secondary sites to form metastases (M) at various timepoints during
tumour evolution. Clones leaving early have greater genetic divergence between the primary tumour and metastases (a) compared with later
disseminating clones (c–e). Clones can depart as single circulating tumour cells (CTC) or in clusters to seed monoclonal (b) and polyclonal (d)
metastases, respectively. While driver mutations in metastases are the same as in the primary tumour, whole-genome doubling (WGD) is a
more frequent genetic feature of metastases. Following seeding and outgrowth at a secondary site, metastatic clones can further disseminate
to cross-seed (c), reseed (e) and self-seed, resulting in a complex clonal landscape.
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However, Hu et al. presented data from CRC, breast and lung
cancer patients that suggest metastatic seeding might occur early,
even before the primary tumour is clinically detectable, irrespec-
tive of the site of metastatic colonisation (Fig. 1a).34,43 Spatio-
temporal data examining the timing and speed of spread from
oesophageal cancer patients showed that in the majority of cases,
metastatic spread from the primary site was rapid,31 similarly
challenging the idea of metastasis as a late event. Interpretation of
the genetic data are, however, complicated by the fact that the
genetic divergence between the most advanced primary tumour
clone and metastases, or the time at which a metastasis is
clinically detected, does not necessarily reflect the timing of
metastatic seeding.
Depending on the timing of metastatic seeding, the extent to
which the primary tumour and established metastases evolve will
vary. This parallel evolution leads to genetic differences, but it can
also converge on shared genetic pathways to ultimately bring out
the same consequence. Multi-region profiling of primary-
metastatic prostate cancer pairs revealed in one case that
metastases and the primary tumour were highly unrelated,
suggestive of early divergence followed by parallel evolution,
while, in another case, the metastatic subclone was found in the
primary tumour but had accumulated additional mutations.32
Similar results have been described in renal cancer, where parallel
evolution of metastatic clones leads to similar but not identical
genetic alterations across different metastatic clones.33,44 In
pancreatic cancer, analysis of the primary tumours and metastases
from various distant sites revealed shared structural rearrange-
ments that occurred early in tumour evolution and varying
degrees of genetic divergence between primary and metastases,
which was consistent with on-going parallel evolution.45
Based on the current data, it therefore appears that cancer
types or even individual tumours are not constrained to a
particular model of metastatic evolution. Rather, metastases are
characterised by varied timings and trajectories of dissemination,
in which distinct metastasis-competent clones leave the primary
site at different timepoints to seed, reseed and cross-seed multiple
metastases, all the while acquiring a more complex genetic
landscape. The timing of seeding seems to be key in how these
clones evolve. In some cancers, metastases are closely related to
existing primary tumour clones, whereas in others, metastases
have undergone significant further evolution in parallel.
Mutational profiles of metastatic tumours
In general, specific driver gene mutations that are exclusive to
metastases have not been identified to date despite extensive
sequencing data from various cohorts and cancer types. In most
cases, unique genetic alterations can be detected in the
metastatic site when compared with their respective primary
tumours but these changes are not consistent across metastases
and also occur in primary sites in other contexts.33,38,42,44,46,47
In line with these observations, mathematical modelling using
data from treatment-naïve patients predicted that the primary
tumours and their metastases share the same driver mutations.48
Reiter at al. profiled 76 untreated metastases from 20 patients with
various cancer types and found that all metastases within
individual patients shared the same functional driver gene
mutations. The authors did observe some inter-metastatic
heterogeneity, but these heterogeneous mutations were pre-
dicted to be nonfunctional.48 These observations suggest that the
mutational complements of the primary cell populations are
sufficient for conferring metastatic capabilities.
Although metastases have similar mutational profiles to primary
tumours, they appear to bear driver alterations at a higher
frequency than primary tumours. Priestley et al. characterised
2520 samples of metastatic tumours from 22 solid cancer types.24
Consistent with other results, they found no evidence of driver
mutations that were specific to metastases,24 but they did find
alterations in theMLK4 gene (which encodes mixed lineage kinase 4)
frequently associated with metastatic tumours. MLK4 upregulation
has previously been linked to migratory and invasive phenotypes in
breast cancer cells.49 They also identified candidate driver variants in
over 98% of metastatic tumours; in 62% of patients, these variants
were potentially therapeutically actionable.24 Similarly, another
study profiled somatic alterations in 617 patients with metastatic
breast cancer and concluded that the metastases were genetically
more complex and had a higher mutational burden and clonal
diversity when compared with early breast cancers.50 In addition,
common germline variants of the APOE gene have been shown to
be associated with different outcomes in melanoma. Mice expres-
sing the human APOE4 allele exhibited reduced metastasis relative
to APOE2 mice, suggesting certain genetic lesions can increase
metastatic competence.51
Even though the same mutations seem to drive the growth of
primary and metastatic cancers, the efficiency with which a
particular clone seeds metastasis might still depend on its
mutations. Turajilic et al. tested this notion directly by comparing
the genetic architecture of different primary tumour clones with
that of those that formed metastases in the same patients in renal
cancer. The only genetic alteration that was significantly
associated with metastasis was loss of 9p, a region which contains
the cyclin-dependent kinase inhibitor 2A and 2B tumour
suppressor loci. The authors also found that primary tumours
with PBRM1-SETD2 and PBRM1-PI3K driver mutations and high
tumour heterogeneity were associated with attenuated progres-
sion.33 These results suggest that certain genetic alterations are
capable of increasing metastatic competence but that these
mutations are not exclusive to metastasis as they are already
selected for in primary tumours.
Further evidence for the lack of a unifying metastasis-specific
signature comes from experimental models of metastasis. In
highly metastatic subclones isolated from human-derived cancer
cell lines, the selection of pre-existing genetic mutations, such as
KRASG12D and BRAFG46V, was associated with increased metastatic
competence, suggesting no additional mutations were required.52
In a genetically engineered mouse model of CRC, mice bearing
mutations in four genes commonly found in primary human
cancers (Apcfl/fl, KrasLSL-G12D, Tgfbr2fl/fl and Trp53fl/fl) formed
metastases.53 Interestingly, no metastases were seen in mice that
lacked the full set of four mutations.53 Consistent with this
observation, exome sequencing data from CRC patients with brain
or liver metastases revealed that various combinations of early
driver genes collectively disrupting key signalling pathways (WNT,
TP53, TGFB, EGFR and cellular adhesion) were significantly
enriched in metastases.34 These studies suggest that although
no specific mutations underlying metastasis seem to exist, specific
combinations of mutations in primary tumours, possibly acquired
in a particular order, can lead to enhanced metastatic compe-
tence. In addition, the existence of genes whose overexpression
inhibits metastasis but not primary tumour growth in experi-
mental systems (i.e. functionally defined metastasis suppressors)
suggests that there are pathways specifically linked to metastasis,
raising the possibility that further sequencing could potentially
lead to the identification of metastasis-specific genetic driver
lesions that have yet to be discovered.54
Chromosomal aberrations and metastasis
The genetic feature most clearly associated with metastatic cancer
is whole-genome doubling (WGD). Chromosomal instability (CIN)
is a process resulting in chromosome abnormalities and aneu-
ploidy, which correlate with poor prognosis and metastasis across
multiple cancer types.25,55–57 Specifically, an increase in chromo-
some aberrations during tumour progression has been reported in
renal, CRC, prostate, pancreatic and breast cancer in independent
studies,42,45,58–61 as well as in mouse models of melanoma62 and
pancreatic cancer.63 WGD has been found in up to 80% of
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metastases in certain types of cancer.24 Although WGD is
commonly found in metastases, this varies depending on the
cancer type and is not exclusive to metastasis as it has been
observed in around 30% of primary tumours as well.64 Interest-
ingly, cancer cells displaying WGD may be more tolerant of CIN in
general, possibly facilitating further genetic evolution of
metastases.65
One possible explanation for the association between CIN and
metastasis is that CIN is a mechanism for the genetic amplification
of oncogenic signalling, resulting in more aggressive cancer
clones. In support of this notion, Priestley et al. found twice as
many driver gene amplifications in samples with WGD events.24 In
addition, multi-region profiling of primary and metastatic CRC
found that chromothripsis (a mutational process in which
chromosome shattering leads to complex rearrangements) and
focal amplifications of MYC were features of metastatic tumours,56
while another study also identified MYC as well as YAP1
amplifications in brain metastases from lung cancer patients.47
Gains in the number of oncogenic mutant KRAS alleles have been
reported in pancreatic cancer metastasis.45 Another potential
mechanism by which CIN can lead to metastasis has been
proposed by Bakhoum et al.66 In this model, high CIN results in
increased levels of cytosolic DNA, which, in turn, triggers the
cGAS-STING cytosolic DNA sensing pathway and downstream
activation of noncanonical nuclear factor (NF)-κB signalling,
leading to epithelial–mesenchymal transition (EMT). Inhibition of
NF-κB signalling was found to decrease metastasis in a human-
derived cancer cell line model.66 Alternatively, the possibility also
remains that CIN could be a consequence of tumour evolution
rather than a functional driver of it. For instance, loss of p53
function is associated with poor prognosis and can lead to CIN;67 it
is therefore possible that CIN is a passenger event that occurs as a
consequence of a driver event such as p53 inactivation. Analyses
of large cancer genome datasets have revealed that WGD is
enriched in tumour types with extensive loss-of-heterozygosity
(LOH), suggesting that WGD might be selected for during tumour
evolution to mitigate deleterious somatic mutations and somatic
copy number changes in regions of LOH.68
Despite a lack of comprehensive understanding of the
mechanisms underlying the association between CIN and
metastasis, the evidence linking these features is compelling
and indicates that CIN could be a possible genetic means by
which cancer clones acquire metastatic capabilities.
Therapy- and immunity-induced selection and metastasis
The genetic evolution of metastatic tumours is shaped by tumour-
extrinsic factors. The strong selective pressures induced by
exposure to treatment result in acquired drug resistance muta-
tions, parallel evolution and relapse. Drug-treated metastases have
been reported to harbour private driver mutations unlike
untreated metastases.43 Although resistance mutations can arise
de novo,69 they also frequently pre-exist as minor subclones.70 In
patients with breast cancer, around 20% of metastatic tumours
develop mutations in the gene encoding oestrogen receptor 1
(ESR1) during endocrine therapy.71 Larger-scale reports have
suggested that therapy-resistant metastatic breast cancer could
also acquire new driver alterations in genes other than ESR1, such
as those involved in the mitogen-activated protein kinase (MAPK)
pathway.72 In another study of five patients, ERBB2 mutations were
acquired during endocrine therapy.73 ESR1 and TP53 driver
mutations, as well as amplifications in MDM4, FGFR1 and CCND1,
were detected in patients relapsing after endocrine therapy, and
mutations in SWI/SNF genes were found following taxane
chemotherapy.42 In addition, parallel evolution of distinct PTEN
mutations was detected in metastases following acquired resistance
to an inhibitor of phosphatidylinositol 3-kinase α.74
In addition to therapy-induced mutations, pressures from the
tumour microenvironment can provide an environment for
positive selection and parallel evolution of metastasis-initiating
cells. One such example comes from a longitudinal study of
patients with metastatic CRC in which genetic data were
consistent with parallel selection during metastasis evolution
dependent on the strength and quality of the local immune
response: metastatic clones could be traced back to immune-
privileged clones that were capable of escaping the intrameta-
static immune microenvironment, while the eliminated clones
were immunoedited.75 Interestingly, LOH of HLA, which impairs
the ability of the immune system to recognise tumour antigens, is
associated with metastasis,76 and different metastases can be
characterised by very different immune microenvironments even
within a single patient.77,78 These observations highlight not only
the continuous genetic evolution of metastases influenced by
changing environmental pressures, but also the challenges of
keeping up with the evolving metastases during therapy.
EPIGENETIC ORIGINS OF METASTASIS
As outlined in the previous section, specific metastasis-causing
mutations have not been identified. Nevertheless, primary cancers
with similar tumour-initiating mutations and other early mutations
can eventually progress towards vastly different metastatic
phenotypes, specific transcriptional programmes correlate with
poor patient prognosis and metastasis in several, if not all, tumour
types, and stable highly metastatic cancer clones with distinct
gene expression programmes can be isolated from multiple
different human- and mouse-derived experimental cancer mod-
els.33,79 Moreover, extensive experimental data support the idea
that these gene expression programmes contain functionally
important mediators of various metastatic phenotypes.80 So,
specific transcriptional programmes appear to underlie the
development of metastases, but they don’t seem to be induced
by specific metastasis-associated mutations. This presents a
central problem: how do the metastatic transcriptional traits arise?
Various heritable nongenetic, i.e. epigenetic, mechanisms have
been linked to cancer progression. For example, large-scale
alterations in DNA methylation, chromatin accessibility, histone
modifications and 3D chromatin conformation are typically
observed in cancer and many such alterations also correlate with
cancer prognosis and metastasis.79 Strong evidence links multiple
different factors such as mutations in genes that encode for
chromatin-associated proteins (e.g. members of the SWI/SNF
chromatin remodelling complexes),81 oncometabolites82 or envir-
onmental factors such as hypoxia83 to altered chromatin in cancer.
However, as most of these epigenetic mechanisms associated with
cancer development and progression cause unspecific (i.e. not
directly guided by the underlying DNA sequence) perturbations in
chromatin states, it is unclear how they alone can result in the
activation of specific metastatic transcriptional programmes. The
role of widespread chromatin alterations in metastasis may
therefore be to facilitate the phenotypic evolution of genetically
activated oncogenic programmes, allowing them to aberrantly
activate various developmental, regenerative and stem-cell path-
ways in contexts where these pathways increase metastatic fitness
(Fig. 2). The general epigenetic mechanisms that underlie cancer
progression have been reviewed elsewhere.79 Here we focus on
the nature of the epigenetically encoded cellular programmes that
facilitate metastasis and discuss their interaction with genetically
activated oncogenic pathways.
Developmental and regenerative origins of metastatic
programmes
One possible origin of metastatic traits is the activation of normal
developmental or regenerative programmes in the wrong context.
For example, L1CAM is a neural cell adhesion molecule that
mediates metastatic colonisation in lung, breast, colorectal and
other cancer types.84–86 In normal intestine, L1CAM is only
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expressed when epithelial damage occurs. In CRC, L1CAM is
dispensable for adenoma formation, but is activated as tumours
progress, in response to the loss of epithelial integrity as a result of
the loss of E-cadherin in cell–cell junctions by a mechanism that
requires the removal of REST (a regulator of the Polycomb
receptor complex 1—PRC1) from an L1CAM enhancer. The
transcriptional programmes induced by L1CAM govern the
interaction between metastatic cells and the stroma in distant
organs and are important for metastasis growth.86 Similarly, the
transcription factors RUNX2, which is essential for bone develop-
ment and osteoblast differentiation,87,88 supports metastasis in
osteosarcoma,89 nuclear factor 1 B‑type (NFIB) activates neuronal
enhancer programmes in support of lung cancer metastasis,90 and
FOXA1 supports pancreatic cancer metastasis through a transcrip-
tional program similar to those normally active in embryonic
foregut endoderm.91 Interestingly, BORIS, a germ-cell-specific
paralogue of the zinc-finger-binding protein CTCF, is over-
expressed in several cancers. In treatment-resistant neuroblas-
toma, BORIS-regulated alterations in enhancer–promoter
interactions support advanced cancer phenotypes,92 suggesting
a possibility that similar mechanisms could underlie the activation
of other developmental programmes in cancer as well. Thus,
programmes that normally support tissue development and
regeneration are constitutively and aberrantly activated in cancer
cells, leading to enhanced metastatic fitness. However, how the
activation of these programmes is linked to the genetic
aberrations that drive carcinogenesis remains in most contexts
poorly understood.
In addition to regulating lineage-specific developmental and
regenerative programmes, factors that control lineage transitions
during development can also support metastatic phenotypes. An
obvious example is provided by the various mediators of EMT,
which can establish cellular states with enhanced metastatic
potential.93 Specific transcription factors, such as SNAI1, SNAI2,
TWIST1 and ZEB1, orchestrate and coordinate the EMT pro-
gramme. The activation of EMT factors has been widely studied
and a remarkably complex picture has emerged with links to
microenvironmental signals, oncogenic signalling pathways,
epigenetic factors such as DNA methylation, metabolism and
post-transcriptional regulation.82,94–97 Some, but not all, EMT
transcription factors are important for metastasis in pancreatic,98
breast99,100 and skin cancer101,102 as well as other cancer
types.96,103 Other EMT events, however, such as loss of E-
cadherin expression, have been shown to inhibit metastasis;104
additional examples of context specificity of EMT factors as
mediators of metastasis also exist.105 Hence, the role of EMT as a
general phenomenon in metastasis, in contrast to the specific
effects of the various EMT factors in different cancer contexts, still
needs further clarification, but it is clear that several of these
factors facilitate metastatic progression at least in some cancers
(Fig. 3a).
Homoeostatic stem-cell programmes as a source of metastatic
fitness
In many cancers, tumour propagation depends on a subpopula-
tion of cells with stem-like characteristics. Although some of the
stemness programmes might be dependent on oncogenic path-
ways, others seem to be closely related to homoeostatic stem-cell
programmes.17,106 An interesting example of the association
between stem-cell programmes and cancer has been described
in CRC, where an Lgr5-positive subpopulation with tumour- and
metastasis-initiating capabilities has been identified.107 Lgr5 also
marks normal intestinal stem cells, suggesting that the physiolo-
gical intestinal stem-cell programmes might be conserved in
cancer. Other studies have, however, highlighted the role of Lgr5-
negative CRC cells in the initiation of metastasis,108 suggesting
that the relationship between tumour subpopulations could be





























Fig. 2 Epigenetic mechanisms alter oncogenic signalling in support of metastasis. Genetically activated pathways and tissue-specific
cellular programmes drive oncogenic signalling in primary tumours (left). The phenotypic output of these pathways can change via several
epigenetic mechanisms ranging from alterations in DNA methylation (a), chromatin accessibility (b), histone modification states (c) and higher
order chromatin conformation (d). As these epigenetic mechanisms are in principle unspecific, the actual phenotypes that emerge are
dictated by the oncogenic programmes that are active in the cells. Some of these phenotypes will enhance oncogenic signalling and get
selected for. The phenotypic output of the oncogenic pathways that drive primary tumour formation thus evolves via epigenetic alterations to
support metastatic cancer phenotypes (right).
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the tumour suppressor adenomatous polyposis coli (APC) and its
known function as an inhibitor of the Wnt signalling pathway that
regulates Lgr5 expression provides one of the clearest examples of
the close links between cancer driver mutations and homoeostatic
stem-cell programmes as a critical determinant of tumour
phenotypes, including metastasis-initiating potential. Another
example comes from lung cancer, in which SOX2 and SOX9, two
transcription factors associated with a stem-cell-like state in lung
and breast cancer cells, support metastatic progression in
experimental mouse models.109,110 Both SOX2 and SOX9 are also
important for the survival of disseminated lung and breast cancer
cells in secondary organs under immune surveillance, as well as
metastatic outgrowth under permissive conditions.110 Hence, in
parallel with developmental and regenerative pathways, various
homoeostatic stem-cell programmes can be co-opted by cancer
cells, and this can lead to enhanced metastatic fitness (Fig. 3a).
Enhanced oncogenic signalling as a driver of metastasis
Instead of co-opting entire developmental, regenerative or
homoeostatic programmes, another possible mechanism by
which cancer clones can acquire metastatic traits is through
optimising or fine-tuning the phenotypic output of already
activated oncogenic signalling pathways at the transcriptional
level. Such changes in transcriptional output can arise through
different routes and depend on both genetic and epigenetic
alterations. For example, in prostate cancer, mutations in FOXA1
lead to altered chromatin states that modulate hormone-
dependent transcriptional signalling through the androgen
receptor.111 Interestingly, a specific subtype of FOXA1 mutation
with increased DNA affinity and chromatin-binding pattern is
enriched in metastatic tumours and causes invasive phenotypes in
tissue culture assays, possibly via a Wnt-dependent mechanism.112
Other experimental and clinical evidence also supports the role of
the Wnt pathway in prostate cancer metastasis.113 Specific cancer
driver mutations can thus directly modulate the epigenetic
landscape of a cancer cell, consequently leading to a more
aggressive metastatic phenotype.
The functional output of oncogenic signalling can also be altered
by changes in chromatin landscapes without specific mutations. In
oestrogen receptor (ER)-positive breast cancer, the YY1 transcription
factor modulates ER signalling, which leads to disease progression;114
and in osteosarcoma, metastatic lesions show AP-1-dependent
enhancer activation.115 In VHL-mutant renal cancer, the functional
output of the tumour-initiating VHL–HIF2A pathway is altered in
metastatic clones through NF-κB-dependent co-option of specific
lymphoid enhancers upstream of the chemokine receptor
CXCR4.116,117 In this context, both HIF2A and NF-κB operate through
separate distal enhancers, the combined action of which is required
for expression of CXCR4 and consequent enhanced metastatic
competence. As HIF2A is stabilised in renal cancer by tumour-
initiating mutations in the VHL tumour suppressor, these data
provide detailed insight into the mechanisms of interaction between
cancer driver mutations and epigenetic events, and how this leads to
cancer progression. General support for aberrant enhancer activation
states in association with cancer progression has emerged from pan-
cancer analyses.118,119 Altered chromatin landscapes thus allow
oncogenic pathways to activate distinct target genes in some cancer
clones, which can lead to increased metastatic fitness (Fig. 3b).
Microenvironmental cues as inducers of metastatic oncogenic
signalling
Apart from their random acquisition of mutations, it is not obvious
how cancer cells acquire the capability to constitutively activate
various transcriptional programmes that remain transient under
physiological conditions. Although some transcriptomic rewiring
might be caused by general stress signalling associated with
tumour growth,120 exposure to various microenvironmental
factors, such as signalling molecules, stromal cells, metabolites
or hypoxia could—in a premetastatic but already advanced cancer





























Fig. 3 Epigenetic origins of metastatic transcriptional programmes. Aberrant activation of developmental and regenerative programmes,
mediators of epithelial–mesenchymal transition (EMT), and stem-cell functions in cancer cells can lead to enhanced metastatic fitness (a).
Genetic and epigenetic alterations resulting in optimisation of the phenotypic output of already activated oncogenic signalling pathways lead
to the acquisition of metastatic traits. In kidney cancer, the output of the VHL–HIF-2A pathway is altered in metastatic clones through nuclear
factor (NF)-κB-dependent enhancer co-option (b). Microenvironmental stimuli induce metastatic oncogenic signalling (c, d). The tumour
microenvironment is characterised by persistent inflammation, inducing NF-κB activation and the expression of metastasis genes (c). Tumour
hypoxia activates HIF1 and HIF2-dependent transcriptional programmes that have been linked to metastatic progression (d).
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increase metastatic fitness. Accumulating experimental evidence
is starting to support such a model. For example, persistent
inflammation is able to induce NF-κB activation in renal cancer
cells,121 which, on a background of genetically activated HIF2A
signalling, can lead to the expression of mediators of metasta-
sis.116,121 Enhanced inflammatory signalling through NF-κB can
also modulate Wnt signalling in CRC, highlighting the general
relevance of inflammation as a modulator of oncogenic signal
output.122
In addition to inflammation, other environmental cues could, in
the context of already activated oncogenic signalling, lead to
stable activation of metastasis genes. For example, HIF1- and HIF2-
dependent transcriptional programmes have been linked to
metastatic progression in several tumour types,123–126 suggesting
that activation of the hypoxia response in primary tumours might
be important for metastatic tumour growth in the secondary
organs. Some of these effects can be explained by constitutive
activation of HIF1 and HIF2 in the absence of hypoxia, but low
oxygen tension can also lead to stable changes in gene
expression.83,127,128 Interestingly in lung cancer, antioxidant
exposure can lead to the activation of BACH1, a transcription
factor that, in turn, promotes a specific glycolysis-dependent
metabolic programme important for metastatic growth.129,130 This
suggests that the specific metabolic milieu of cancer cells could
lead to stable alterations in their transcriptomes, consequently
enhancing metastasis. In line with this, extracellular fatty acids can
enhance oral carcinoma metastasis.131 Collectively, these data
point to an important role for the tumour microenvironment in
the stable epigenetic reprogramming of cancer cell transcrip-
tomes, which can lead to enhanced metastasis (Fig. 3c).
CONCLUSIONS
Almost two decades ago, in the absence of present-day insight
from the large-scale genomic analysis of metastasis, Bernards and
Weinberg proposed that metastatic progression is driven by the
same oncogenic mutations as primary tumours.132 This prediction
has since then been largely validated by extensive genetic data.
However, it is also clear that the phenotypic output of oncogenic
mutations is different in different cancer clones, and that these
differences constitute important determinants of metastatic
fitness. This variability in oncogenic output can be largely ascribed
to various epigenetic alterations that shape the transcriptomes of
cancer cells.79 However, while specific examples of these
mechanisms are being unravelled by detailed functional analysis
in different contexts, how cancer mutations interact with various
developmental, homoeostatic and regenerative programmes in
support of cancer progression and metastasis is still poorly
understood. A striking result from cancer genome studies is that
mutational patterns even in metastatic tumours remain strongly
tissue specific.24,81 This suggests that in order to understand the
origins of metastatic cancer traits, a comprehensive understanding
of how physiological and oncogenic programmes co-operate at
different stages of cancer progression must be sought. Such
understanding should also result in the identification of genetic
and epigenetic biomarkers for early detection of metastasis.
Current efforts on multiple fronts are working towards this goal.
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